Study Detail

A Phase 3 COVID-19 Vaccine Study

A Randomized, Double-blind, Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Status: In Setup

Type: Interventional

Funder: Janssen-Cilag Ltd

Sponsor: Janssen-Cilag Ltd

CI: Professor Saul Faust

IRAS-Number: 288552

CPMS-ID: 46804

Approval Date: 28 August 2020

Description:

The aim of this study is to evaluate the efficacy, safety, and immunogenicity of Ad26.COV2.S in participants with higher risk for COVID-19 (based on age, gender, race / ethnicity, profession, comorbidity) living in, or going to, locations with high SARS-CoV-2 activity, after administration of two doses of study vaccine.

Back to listing